Purchase this article with an account.
RM Feldman; A Comparison of Fixed Combination of Latanoprost and Timolol with Fixed Combination of Dorzolamide and Timolol (COSOPT) in Patients With Elevated Intraocular Pressure: A Three-month Masked Evaluator, Phase IIIb, Multicenter Study in the United States (XALCOM vs. COSOPT) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):295.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Reducing intraocular pressure slows progression of glaucomatous optic neuropathy and control of IOP remains the principal goal of glaucoma treatment. Satisfactory control is not always achieved with monotherapy. Fixed combinations provide advantages in compliance, efficacy and reduced side effects. The primary objective of this study was to compare the IOP lowering efficacy of a fixed combination of latanoprost 0.005% and timolol 0.5% (Xalcom) QD to a fixed combination of dorzolamide 2% and timolol 0.5% (Cosopt) BID in patients with elevated IOP. Methods: 251 patients with uni or bilateral primary open angle glaucoma or ocular hypertension received either Xalcom once daily or Cosopt twice daily in a three month multicenter, randomized, parallel group, investigator masked study. The primary efficacy variable was mean change in diurnal IOP from baseline at month 3 analyzed using ANCOVA, baseline diurnal IOP as covariate and treatment and center as independent variables. Results: Both Xalcom and Cosopt produced statistically significant reductions in baseline mean diurnal IOP (P < 0.0001). The adjusted mean IOP reductions were 8.4 mm Hg for Cosopt and 9.4 mm Hg for Xalcom (P < 0.025). The frequency of adverse events was similar between the two groups. Conclusions: Once daily Xalcom is significantly more efficacious in lowering IOP than twice daily Cosopt in patients with primary open angle glaucoma or ocular hypertension.
This PDF is available to Subscribers Only